Randomized trial identifies microRNAs as biomarkers for high-grade cervical lesions in high-risk HPV-positive women, suggesting their clinical utility.
Background Cervical cancer (CC) is the fourth leading cause of cancer death in women worldwide. High-risk human papillomavirus (HR-HPV) testing is highly sensitive but lacks specificity for identifying women at risk of progression. Reliable biomarkers are urgently needed to identify HR-HPV-positive women most likely to develop cervical cancer. Aberrant microRNA (miRNA) expression contributes to HPV-driven carcinogenesis and represents a promising diagnostic tool. Methods Cervical scrape samples from HR-HPV-positive women were histologically classified as low-grade (≤CIN1) or high-grade (CIN2/3). Total RNA was extracted and small RNA sequencing performed to identify differentially expressed miRNAs. Bioinformatic analyses included clustering, ROC curves, logistic regression, and functional enrichment. Selected candidates were validated byRT-qPCR in independent samples. Results Nineteen dysregulated miRNAs distinguished low- from high-grade lesions, six linked to viral and cancer pathways. Three (hsa-miR-501-3p, hsa-miR-1271-5p, hsa-miR-9-5p) were validated by RT-qPCR and showed strong discriminatory capacity. hsa-miR-501-3p reached high diagnostic accuracy (AUC = 0.88), which improved to 0.94 when combined with the others. The validated signature achieved high sensitivity and specificity for detecting high-grade lesions. Conclusion This pioneering study in Colombia using cervical scrapes demonstrates that miRNAs are potential biomarkers for high-grade cervical lesions and that this clinically relevant, minimally invasive sample routinely collected in screening supports their use.
No takes yet. Share an insight, caveat, or question.
Guarnizo et al. (2026) studied this question.